[Treatment of primary vascular pulmonary hypertension with the combined therapy using p-hydroxyphenyl-orciprenaline (Berotec) and hydroxy-isopropylamino-propoxyacetanilide (Dalzic)].
D000083:Acetanilides / Q000627:therapeutic use; D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000605:Amino Alcohols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005069:Evaluation Studies as Topic; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D009921:Metaproterenol / Q000627:therapeutic use*; D010636:Phenols / Q000627:therapeutic use; D011437:Propylamines / Q000627:therapeutic use
D000083:Acetanilides; D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D010636:Phenols; D011437:Propylamines; D009921:Metaproterenol
Die therapeutische Beeinflussung der primär vaskulären pulmonalen Hypertonie mit der Kombinationstherapie von p-Hydroxyphenyl-orciprenalin (Berotec) und Hydroxyisopropylamino-propoxy-acetanilid (Dalzic.